TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00698997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model
Description: Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching \& coaching parents to use the ESDM in all natural caretaking routines \& play periods with their child. Parents are taught \& coached on 1 aspect of the ESDM each week in the clinic session, \& then practice it at home daily in natural family routines \& play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines \& play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard community care
Description: Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
Study: NCT01347775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (URES HS730)
Description: It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training (URES HS730)
Description: Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
Study: NCT03182985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
Study: NCT05659784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
Study: NCT04248387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
Study: NCT01415128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Once a day dosing of Omeprazole (40 mg) for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Single dose of Rosiglitazone (8 mg) for 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: Single dose of Desipramine (50 mg) for 1 day
Study: NCT03410459

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DEXA (= Dual-energy x-ray absorptiometry)
Description: measurement of vertebral bone and hip bone mineral density

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DEXA (= Dual-energy x-ray absorptiometry)
Description: measurement of vertebral bone and hip bone mineral density
Study: NCT02064920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for donepezil hydrochloride capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for donepezil hydrochloride capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg donepezil hydrochloride capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg donepezil hydrochloride capsule.
Study: NCT01614938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
Study: NCT00290186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Treatment
Description: 100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Air Treatment
Description: 14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
Study: NCT01841463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: - In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib (Zelboraf®)
Description: * In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~* In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~* Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
Study: NCT04354220

Intervention type: DIAGNOSTIC_TEST
Intervention: capnography monitoring
Description: routinely used capnography monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: capnography monitoring
Description: routinely used capnography monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: capnography monitoring
Description: routinely used capnography monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: capnography monitoring
Description: routinely used capnography monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gas
Description: Routinely taken arterial blood gas values

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gas
Description: Routinely taken arterial blood gas values

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gas
Description: Routinely taken arterial blood gas values

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gas
Description: Routinely taken arterial blood gas values
Study: NCT03388918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Blood pressure (A\&D Medical UA 767PBT), weight (A\&D Medical UC-321PBT), step counters(Fitbit Zip \& Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) \& transmitter (Qualcomm Life, QWH-HUB-V1.0E)
Study: NCT04801875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Exercise
Description: The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Exercise
Description: The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
Study: NCT01591525

Intervention type: BEHAVIORAL
Intervention: Education on risk factors for Type II Diabetes
Description: one-on-one education provided by a nurse practitioner or physician

Intervention type: BEHAVIORAL
Intervention: Education on risk factors for Type II Diabetes
Description: one-on-one education provided by a nurse practitioner or physician
Study: NCT01005745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to remove a tumor for growth of TIL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Lymphodepletion
Description: Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Transfer
Description: T-cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose IL-2
Description: Beginning approximately 12 - 16 hours after cell infusion.
Study: NCT01739569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary treatment
Description: Dietary treatment with healthy lunch and snack meal during working hours
Study: NCT02632565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study: NCT02878551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation program
Description: multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
Study: NCT01777412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02237781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Description: The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
Study: NCT00890253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect)
Description: 20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: 1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 1 mg q12 everolimus (Certican) po starting on 10th post-operative day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
Study: NCT04173715

Intervention type: BEHAVIORAL
Intervention: Older Adults Group.
Description: Physical activity and energy expenditure quantification

Intervention type: BEHAVIORAL
Intervention: Low Physical Function Status Group
Description: Physical activity and energy expenditure quantification

Intervention type: BEHAVIORAL
Intervention: Low Physical Function Status Group
Description: Physical activity and energy expenditure quantification

Intervention type: BEHAVIORAL
Intervention: Medium Physical Function Status Group
Description: Physical activity and energy expenditure quantification

Intervention type: BEHAVIORAL
Intervention: Medium Physical Function Status Group
Description: Physical activity and energy expenditure quantification

Intervention type: BEHAVIORAL
Intervention: High Physical Function Status Group
Description: Physical activity and energy expenditure quantification

Intervention type: BEHAVIORAL
Intervention: High Physical Function Status Group
Description: Physical activity and energy expenditure quantification
Study: NCT04202523

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMRT & SBRT
Description: Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
Study: NCT02964299

Intervention type: DEVICE
Intervention: Mandibular advancement bite block
Description: Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
Study: NCT01255969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Personalized exercise program
Study: NCT01387165

Intervention type: DRUG
Intervention: Treatment
Description: were receiving an oral hypoglycemic agent (OHA) or insulin
Study: NCT00418665

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531
Description: AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531
Description: AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531
Description: AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive placebo via subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive placebo via subcutaneous injection.
Study: NCT00918047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-804O
Description: Open Label study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-804O
Description: Open Label study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-804O
Description: Open Label study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-804O
Description: Open Label study
Study: NCT01293968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen, Diphenhydramine and Aluminium MgS
Description: 3 times daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine and Aluminium MgS
Description: 3 times daily for 3 days
Study: NCT02603471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational group
Description: A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging CBT (TXT-CBT)
Description: Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
Study: NCT04224844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
Study: NCT04084106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Description: Oral administration
Study: NCT04952740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPC+PCI
Description: Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No IPC
Description: Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
Study: NCT00853749

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL intramuscular injection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Collection of 10 mL of blood
Study: NCT03919929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3mg and 7mg [Rybelsus]
Description: Once daily oral tablet of semaglutide for 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss diet
Description: Prescribed weight loss diet to match weight loss in Drug arm
Study: NCT00744133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NF54 P. falciparum isolate
Description: 1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NF54 P. falciparum isolate
Description: 1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
Study: NCT01188720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: 30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
Study: NCT00591214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (Telaprevir)
Description: Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
Study: NCT00495820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard inactive pill.
Study: NCT00161460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: colorectal cancer screening intervention
Description: Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
Study: NCT03653130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crossroads Orchestra Participatory Music Program
Description: The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
Study: NCT04169022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Sample collection blood and/or bone marrow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sample collection
Description: Sample collection blood and/or bone marrow